Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of remibrutinib in secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Started Nov 2025; status: recruiting.
02
Drugs
remibrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT07225504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225504.